Linked Life Data

11187134

Source:http://linkedlifedata.com/resource/pubmed/id/11187134

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
50
pubmed:dateCreated
2001-1-16
pubmed:abstractText
In recent years, a more detailed understanding of the pathogenesis of several inflammatory skin diseases, and developments in biotechnology, have made it possible to design specific response modifiers, which hold a potential for greater effectiveness and fewer side effects than do the systemic therapies in current use in cases of severe psoriasis, contact dermatitis and atopic dermatitis. The immune system plays a pivotal role in the pathogenesis of inflammatory skin diseases, and this is where such biological response modifiers as monoclonal antibodies, recombinant cytokines, or fusion proteins may be effective. Several biological response modifiers have already shown positive results in phase II clinical trials; phase III trials are being carried out.
pubmed:language
dan
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0041-5782
pubmed:author
pubmed:issnType
Print
pubmed:day
11
pubmed:volume
162
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6820-4
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
[Biotechnological pharmaceuticals and their potential use in inflammatory skin diseases].
pubmed:affiliation
Dermatologisk afdeling, Amtssygehuset i Gentofte.
pubmed:publicationType
Journal Article, English Abstract, Review